Q3 Earnings Forecast for Genmab A/S Issued By William Blair

Genmab A/S (NASDAQ:GMAB) – Research analysts at William Blair issued their Q3 2025 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, February 13th. William Blair analyst M. Phipps expects that the company will earn $0.46 per share for the quarter. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. William Blair also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.44 EPS and FY2028 earnings at $4.02 EPS.

GMAB has been the subject of several other reports. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.17.

Genmab A/S Stock Up 2.2 %

Shares of Genmab A/S stock opened at $21.77 on Monday. The company has a market cap of $14.41 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The business has a 50 day moving average price of $20.64 and a 200-day moving average price of $23.02.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the period. Barclays PLC increased its holdings in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC increased its holdings in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.